Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pemigatinib in myeloid/lymphoid neoplasms with FGFR1 rearrangement
NCT03011372Phase 2Completed
- Sponsor
- Incyte
- Start
- Apr 2017
- Primary completion
- Oct 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 11
01
Overview
A Phase 2 trial of pemigatinib in Myeloid/lymphoid neoplasm with FGFR1 rearrangement (MLN-FGFR1), sponsored by Incyte. Started Apr 2017; status: completed.
02
Drugs
pemigatinib
03
Conditions
Myeloid/lymphoid neoplasm with FGFR1 rearrangement (MLN-FGFR1)
Beyond the preview
Go deeper on NCT03011372.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03011372.